CMS Says No, Again, To Modified Moving Average T-Wave Alternans Testing
This article was originally published in The Gray Sheet
In a new proposed decision memo, CMS says it plans to confirm its existing national non-coverage policy on microvolt T-wave alternans diagnostic testing with the modified moving average method.
You may also be interested in...
After cardiologists strongly urged CMS to support MWTA testing using the modified moving average method to determine if patients are at risk of sudden cardiac death, CMS left an opening for local Medicare contractors to decide on coverage rather than retaining a national non-coverage policy.
The Medicare agency says it is reconsidering a 2008 national noncoverage policy for GE Healthcare’s microvolt T-Wave alternans testing tool for evaluating risk of sudden cardiac death, and the potential need for an ICD. An alternative MTWA technique is already covered, but the company that makes that product is going out of business.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker